SRP0228
SMURF2 Active human
recombinant, expressed in baculovirus infected insect cells, ≥80% (SDS-PAGE)
Synonym(s):
E3 ubiquitin ligase SMURF2, MGC138150, SMAD specific E3 ubiquitin protein ligase 2
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Recommended Products
biological source
human
recombinant
expressed in baculovirus infected insect cells
Assay
≥80% (SDS-PAGE)
form
aqueous solution
specific activity
≥0.00049 pmol/min-μg
mol wt
72 kDa
packaging
pkg of 20 μg
storage condition
avoid repeated freeze/thaw cycles
concentration
>0.02 mg/mL
NCBI accession no.
UniProt accession no.
shipped in
dry ice
storage temp.
−70°C
Gene Information
human ... SMURF2(64750)
General description
Human SMURF 2 (GenBank Accession No. NM_022739), amino acids 130-end, with N-terminal DDDDK tag (FLAG), MW = 72 kDa, expressed in a Baculovirus infected Sf9 cell expression system.
Application
Useful in conjunction with E1 and E2 for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.
Unit Definition
One unit is defined as the amount of enzyme required to transfer 1 pmol of ubiquitin to substrate/min at 37°C.
Physical form
Formulated in 25 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.05% Tween-20, 100 μg/ml FLAG peptide, 20% glycerol and 3 mM DTT.
Preparation Note
Thaw on ice. Upon first thaw, briefly spin tube containing enzyme to recover full content of the tube. Aliquot enzyme into single use aliquots. Store remaining undiluted enzyme in aliquots at -70°C. Note: Enzyme is very sensitive to freeze/thaw cycles.
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
The Journal of biological chemistry, 295(36), 12661-12673 (2020-07-17)
The discovery of activating epidermal growth factor receptor (EGFR) mutations spurred the use of EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, as the first-line treatment of lung cancers. We previously reported that differential degradation of TKI-sensitive (e.g. L858R) and
LncRNA LITATS1 suppresses TGF-I?-induced EMT and cancer cell plasticity by potentiating TI?RI degradation.
The Embo Journal, 42, e112806-e112806 (2023)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service